151 related articles for article (PubMed ID: 21195931)
21. [Anemia in chronic renal insufficiency].
Salvati F; Troia C
Minerva Med; 1978 Nov; 69(54):3719-23. PubMed ID: 733054
[TBL] [Abstract][Full Text] [Related]
22. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
Van Wyck DB
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
[TBL] [Abstract][Full Text] [Related]
23. [Lipoprotein oxidation profile in end stage renal disease patients. Role of vitamin C supplementation].
Ramos R; Gómez-Geriqué N; Martínez-Castelao A
Nefrologia; 2005; 25(2):178-84. PubMed ID: 15912655
[TBL] [Abstract][Full Text] [Related]
24. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients.
Fumeron C; Nguyen-Khoa T; Saltiel C; Kebede M; Buisson C; Drüeke TB; Lacour B; Massy ZA
Nephrol Dial Transplant; 2005 Sep; 20(9):1874-9. PubMed ID: 15972322
[TBL] [Abstract][Full Text] [Related]
25. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
27. Ascorbic acid use in hyporesponders to Epoetin alfa.
Gibbs MA
Nephrol Nurs J; 2000 Aug; 27(4):413-5. PubMed ID: 11276634
[TBL] [Abstract][Full Text] [Related]
28. [Pathophysiological characteristics of anemia in patients periodically dialyzed].
Antonov S
Vutr Boles; 1985; 24(2):13-8. PubMed ID: 3898583
[No Abstract] [Full Text] [Related]
29. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
30. Diagnosing and treating anemia and iron deficiency in hemodialysis patients.
Foret JP
Nephrol Nurs J; 2002 Jun; 29(3):292-6. PubMed ID: 12164080
[TBL] [Abstract][Full Text] [Related]
31. [Treatment experience with anemia in chronic kidney failure patients].
Shostka GD
Klin Med (Mosk); 1984 Jun; 62(6):60-6. PubMed ID: 6471800
[No Abstract] [Full Text] [Related]
32. L-carnitine supplementation in the dialysis population: are Australian patients missing out?
Reuter SE; Faull RJ; Evans AM
Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095
[TBL] [Abstract][Full Text] [Related]
33. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
34. Managing erythropoietin hyporesponsiveness.
Kwack C; Balakrishnan VS
Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow blood formation and iron stores in patients with chronic renal failure on maintenance hemodialysis.
Shostka GD
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):769-77. PubMed ID: 6176500
[TBL] [Abstract][Full Text] [Related]
36. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
37. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
38. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
39. Effect of hepatitis C infection on anemia in hemodialysis patients.
Khurana A; Nickel AE; Narayanan M; Foulks CJ
Hemodial Int; 2008 Jan; 12(1):94-9. PubMed ID: 18271849
[TBL] [Abstract][Full Text] [Related]
40. Monitoring considerations in recombinant human erythropoietin therapy.
Ogden DA
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
